Completed PHASE3 INTERVENTIONAL 2-arm NCT00156208

Safety of Treatment of Uterine Fibroids With Asoprisnil

A Phase III, 18-Month, Extension Study to Evaluate the Safety of Asoprisnil in Subjects With Uterine Leiomyomata

Sponsor: Abbott

Conditions Fibroid Uterus Leiomyoma Menorrhagia Metrorrhagia Uterine Fibroids

Interventions Asoprisnil

Updated 6 times since 2017 Last updated: May 27, 2008 Started: Apr 30, 2004 Primary completion: Dec 31, 2006 Completion: Dec 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Fibroid Uterus and Leiomyoma, this trial is completed. The trial is conducted by Abbott and has accumulated 6 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Apr 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Abbott

Data source: Abbott

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.